Circulating tumor DNA detection and quantification in patients with metastatic choroidal melanoma.

Technique development: In first step, the different available techniques will be evaluated for specificity and sensibility using serial dilutions of cell lines with or without GNAQ mutation.

Validation: The tumor DNA detection rate will be estimated from metastatic uveal patient's blood. The investigators will study 40 patients to obtain at least 15 patients bearing a GNAQ mutation in the primitive tumor or in metastasis. With those 15 patients, the investigators will determinate the most sensitive technique and the best cost/efficiency ratio.

Inclusion Criteria:

• Age > or = 18 years.
• Patient with a metastatic choroidal melanoma.
• Patient with tumor or metastasis available for GNAQ (Guanine nucleotide blinding protein) status characterization.
• Patient able to stand a blood collection.
• Signed written informed consent approved by competent authority and ethic committee.

Exclusion Criteria:

• Patient without social protection/insurance.
• Current pregnancy and lactation.
• All social, medical, psychological, situations making the study impossible.
• Person deprived of liberty.

Sponsor will share de-identified data sets. Documents generated under the project will be disseminated in accordance with Institut Curie policies.

Data requests can be submitted starting 9 months after last article publication and will be made accessible for up to 12 months.

Access to trial individual participant data can be requested by qualified researchers engaging in independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a data sharing agreement (DSA).